JP2012255007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012255007A5 JP2012255007A5 JP2012176112A JP2012176112A JP2012255007A5 JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5 JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012176112 A JP2012176112 A JP 2012176112A JP 2012255007 A5 JP2012255007 A5 JP 2012255007A5
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- amino acid
- acid sequence
- peg
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 3
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000057421 human MET Human genes 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23136509P | 2009-08-05 | 2009-08-05 | |
| US61/231,365 | 2009-08-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523344A Division JP2013501033A (ja) | 2009-08-05 | 2010-08-05 | リポカリン突然変異タンパク質の制御放出製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012255007A JP2012255007A (ja) | 2012-12-27 |
| JP2012255007A5 true JP2012255007A5 (2) | 2013-09-26 |
| JP5774557B2 JP5774557B2 (ja) | 2015-09-09 |
Family
ID=43531164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523344A Pending JP2013501033A (ja) | 2009-08-05 | 2010-08-05 | リポカリン突然変異タンパク質の制御放出製剤 |
| JP2012176112A Expired - Fee Related JP5774557B2 (ja) | 2009-08-05 | 2012-08-08 | リポカリン突然変異タンパク質の制御放出製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523344A Pending JP2013501033A (ja) | 2009-08-05 | 2010-08-05 | リポカリン突然変異タンパク質の制御放出製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120201873A1 (2) |
| EP (2) | EP2550958B1 (2) |
| JP (2) | JP2013501033A (2) |
| KR (1) | KR20120099371A (2) |
| CN (2) | CN102612362A (2) |
| AU (2) | AU2010280688A1 (2) |
| BR (1) | BR112012002709A2 (2) |
| CA (1) | CA2770149A1 (2) |
| IN (1) | IN2012DN00407A (2) |
| RU (1) | RU2012107812A (2) |
| WO (1) | WO2011015634A2 (2) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US9701732B2 (en) | 2011-02-28 | 2017-07-11 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| EP2682406B1 (en) * | 2011-02-28 | 2018-05-09 | Korea University Research and Business Foundation | Fusion protein comprising albumin and a retinol-binding protein |
| US10064915B2 (en) | 2011-02-28 | 2018-09-04 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| BR112013027222B1 (pt) * | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
| WO2013068590A1 (en) * | 2011-11-11 | 2013-05-16 | Pieris Ag | Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization |
| MY175188A (en) | 2012-01-09 | 2020-06-13 | Pieris Ag | Methods for preventing, treating or diagnosing disorders |
| ES2604837T3 (es) | 2012-02-02 | 2017-03-09 | Esbatech - A Novartis Company Llc | Formulación de liberación sostenida que contiene anticuerpos para administración ocular |
| US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| JP6138904B2 (ja) | 2012-03-16 | 2017-05-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート |
| US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN103394094B (zh) * | 2013-07-16 | 2015-05-13 | 天津大学 | 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法 |
| CN103360609B (zh) * | 2013-07-16 | 2015-08-19 | 天津大学 | 一种双亲性的蛋白质-高分子键合体及其制备方法 |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US20160151511A1 (en) * | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| KR20240126072A (ko) | 2015-01-27 | 2024-08-20 | 더 존스 홉킨스 유니버시티 | 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제 |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| RU2736590C2 (ru) * | 2016-02-16 | 2020-11-18 | Стронгбридж Даблин Лимитед | Велдореотид, обладающий плохой растворимостью в физиологических условиях, для применения при лечении акромегалии, акромегалии со злокачественным новообразованием, экспрессирующих sst-r5 опухолей, диабета 2 типа, гипергликемии и опухолей, связанных с гормонами |
| US12496279B2 (en) | 2019-04-11 | 2025-12-16 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| DK1087778T3 (da) | 1998-06-08 | 2005-12-19 | Hoffmann La Roche | Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| DK1455839T3 (da) | 1999-10-08 | 2013-05-06 | Nektar Therapeutics | Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf |
| CN1507357A (zh) | 2000-10-31 | 2004-06-23 | PRҩƷ����˾ | 提高生物活性分子传递的方法和组合物 |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| DK2599502T3 (en) | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
| CN1852687B (zh) * | 2003-07-15 | 2014-01-22 | 赢创有限公司 | 控释组合物的制备方法 |
| JP5165240B2 (ja) * | 2003-07-23 | 2013-03-21 | ピーアール ファーマシューティカルズ， インコーポレイテッド | 徐放組成物 |
| WO2005019255A1 (en) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| US8598317B2 (en) * | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| EP2046820B1 (en) * | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
| US8178483B2 (en) * | 2007-03-30 | 2012-05-15 | Colgate-Palmolive Company | Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same |
| RU2009143560A (ru) * | 2007-04-26 | 2011-06-10 | Басф Се (De) | Ферментативный способ получения микрокапсул |
| CN101842084B (zh) * | 2007-07-26 | 2014-11-05 | 亚克蒂斯Ip有限公司 | 包含pcl的微粒及其用途 |
| CA2711984A1 (en) * | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| CN101932598B (zh) * | 2008-01-30 | 2016-12-21 | 皮里斯股份公司 | 具有对人c-met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法 |
| US20090274623A1 (en) * | 2008-01-30 | 2009-11-05 | General Electric Company | In vivo imaging agents for met receptor tyrosine kinase |
-
2010
- 2010-08-05 CN CN2010800348503A patent/CN102612362A/zh active Pending
- 2010-08-05 CA CA2770149A patent/CA2770149A1/en not_active Abandoned
- 2010-08-05 WO PCT/EP2010/061436 patent/WO2011015634A2/en not_active Ceased
- 2010-08-05 EP EP12177932.6A patent/EP2550958B1/en not_active Not-in-force
- 2010-08-05 CN CN201610084958.2A patent/CN106139123A/zh active Pending
- 2010-08-05 RU RU2012107812/15A patent/RU2012107812A/ru not_active Application Discontinuation
- 2010-08-05 IN IN407DEN2012 patent/IN2012DN00407A/en unknown
- 2010-08-05 US US13/388,788 patent/US20120201873A1/en not_active Abandoned
- 2010-08-05 JP JP2012523344A patent/JP2013501033A/ja active Pending
- 2010-08-05 KR KR1020127005597A patent/KR20120099371A/ko not_active Ceased
- 2010-08-05 AU AU2010280688A patent/AU2010280688A1/en not_active Abandoned
- 2010-08-05 BR BR112012002709-3A patent/BR112012002709A2/pt not_active IP Right Cessation
- 2010-08-05 EP EP10747840A patent/EP2461800A2/en not_active Withdrawn
-
2012
- 2012-08-08 JP JP2012176112A patent/JP5774557B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-07 AU AU2016204715A patent/AU2016204715A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012255007A5 (2) | ||
| WO2013096901A8 (en) | Pharmaceutical formulations for fumagillin derivative-phf conjugates | |
| MX368966B (es) | Conjugados de proteina-polimero-farmaco. | |
| EA201390600A1 (ru) | Терапевтические наночастицы с сополимерами с большим молекулярным весом | |
| WO2013130683A3 (en) | Xten conjugate compositions and methods of making same | |
| BR112015000320A2 (pt) | composições farmacêuticas dissuasivas de abuso, de liberação prolongada | |
| JP2013519636A5 (2) | ||
| JP2010215657A5 (2) | ||
| UA114709C2 (uk) | Кон'югат, що містить похідну оксинтомодуліну, fc-ділянку імуноглобуліну та непептидильний полімер, та його застосування | |
| UA111820C2 (uk) | Модифікований зв'язуючий протеїн, що інгібує взаємодію vegf-а-рецептора | |
| JP2012509902A5 (2) | ||
| JP2010534486A5 (2) | ||
| JP2013507132A5 (2) | ||
| BR112014003240A2 (pt) | composição de prostaciclina com liberação sustentada | |
| JP2010202664A5 (2) | ||
| WO2012090150A3 (en) | New cell-penetrating peptides and uses thereof | |
| EP2621480A4 (en) | CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY | |
| JP2011515499A5 (2) | ||
| WO2010064252A3 (en) | Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents | |
| WO2011015634A3 (en) | Controlled release formulations of lipocalin muteins | |
| JP2017523781A5 (2) | ||
| BR112012015977A2 (pt) | composto derivado de poli (ácido lático), método para preparar o composto derivado de poli (ácido lático), complexo do composto de derivado de poli (ácido lático), composição de liberação prolongada de droga, e, método para preparar a composição de liberação prolongada de droga | |
| JP2013515745A5 (2) | ||
| WO2012140647A3 (en) | Albumin binding probes and drug conjugates thereof | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" |